WORLD JOURNAL OF ADVANCE
HEALTHCARE RESEARCH

( An ISO 9001:2015 Certified International Journal )

An International Peer Review Journal for Medical Science and Pharma Professionals

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

World Journal of Advance Healthcare Research (WJAHR) has indexed with various reputed international bodies like : Google Scholar , Index Copernicus , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , Cosmos Impact Factor , Scientific Indexing Services (SIS) , UDLedge Science Citation Index , International Impact Factor Services , International Society for Research Activity (ISRA) Journal Impact Factor (JIF) , IFSIJ Measure of Journal Quality , Scientific Journal Impact Factor (SJIF) , International Scientific Indexing, UAE (ISI) (Under Process) , International Impact Factor Services (IIFS) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Academia , Scope Database , 

ISSN 2457-0400

Impact Factor  :  6.711

News & Updation

  • Article Invited for Publication

    Dear Researcher, Article Invited for Publication  in WJAHR coming Issue.

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.

    .

  • 6th International Conference on Human and Soci

    Venue:FCT Education Resource Center, Abuja- Nigeria                                        September 22-24, 2019

  • New Issue Published

    Its Our pleasure to inform you that, WJAHR April 2024 Issue has been Published, Kindly check it on https://www.wjahr.com/home/current_issues

  • .

    6th INTERNATIONAL CONFERENCE ON EDUCATIONAL TECHNOLOGY AND CURRICULUM STUDIES(ICETC2019) 

     

    Venue: FCT Education Resource Center, Abuja-Nigeria

    September 22-24, 2019

  • WJAHR: New Impact Factor

    WJAHR Impact Factor has been Increased to 6.711 for Year 2024.

  • WJAHR: APRIL ISSUE PUBLISHED

    APRIL 2024 Issue has been successfully launched on APRIL 2024.

Best Paper Awards

World Journal of Advance Healthcare Research (WJAHR)Honored the authors with best paper award, monthly based on the innovation of research work. Best paper will be selected by our expert panel.

Best Article of current issue

Download Article : Click here

Indexing

Abstract

A PRE-CLINICAL EFFICACY AND RANDOMIZED CONTROLLED CLINICAL TRIAL OF NEELKANTHI CHURNA IN THE MANAGEMENT OF TYPE 2 DIABETES MELLITUS

Shivali Mehra*, Vijay Chaudhary, Anjana Mishra and Yogendra S. Padwad

ABSTRACT

Ethnopharmacological relevance: Neelkanthi (Ajuga bracteosa) is a folklore medicine occurring in Western Himalayas. This plant has also been used traditionally in local areas for curing a number of diseases including Diabetes Mellitus. No antidiabetic action of Neelkanthi has been mentioned in Ayurvedic texts, but by virtue of its properties it acts as Madhumehahara Aushada. Hence the present study has been planned to assess the efficacy of Neelkanthi Churna in the management of Madhumeha w.s.r. to Type 2 Diabetes Mellitus on scientific lines. Aim of the study: The present study was carried out to investigate the effect of Neelkanthi Churna (NC) in a mice model of Diabetes Mellitus. Further, its clinical safety and efficacy was assessed in a randomized active-controlled clinical study. Materials and methods: In pre-clinical study, the mice in different groups were kept on high-fat diet for 16 weeks. Thereafter, the mice were treated with 610 and 1220 mg/kg of the NC preparation for subsequent 4 weeks. At the end, different biochemical and histopathological parameters of the NC treated groups were compared with disease control groups. In the clinical trial, 45 patients were randomly divided into following three groups: GROUP I: 15 Patients were managed with NC 3gm twice/day for 12 weeks. GROUP II: 15 Patients were managed with Tab. Metformin 1gm twice/day for 12 weeks. GROUP III: 15 Patients were given both Tab. Metformin 1gm twice/day and NC 3gm twice/day for 12 weeks. At the baseline and endpoint, serum biochemical and haematological parameters were studied. Results: In preclinical experiment, a significant dose-dependent decrease in the Fasting Blood Sugar, total serum cholesterol, triglycerides, low-density lipoprotein (LDL), and increase in high-density lipoprotein (HDL) was observed in NC-treated group compared to disease control. In clinical study, NC significantly decreased the levels of FBS, PPBS, HbA1c and urine sugar following treatment compared to the baseline. However, insignificant change was observed in the studied parameters among NC and Tab. Metformin at the end of the treatment. The other studied biochemical and haematological parameters remained unchanged in all groups following the treatment compared to the baseline. Conclusions: The results of pre-clinical and clinical studies supported the efficacy of NC in Type 2 Diabetes Mellitus. The study also suggested the clinical safety of the NC preparation.

[Full Text Article] [Download Certificate]